ISCOMATRIX™ adjuvant: an adjuvant suitable for use in anticancer vaccines

The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes

Karl Münger, William C. Phelps, Vivien J. Bubb et al. · Journal of Virology · 1989 · 1.3K citations · Full text

Life Sciences, Genetics, Molecular Biology +15

Fc receptors are required in passive and active immunity to melanoma

Raphael Clynes, Yoshizumi Takechi, Yoichi Moroi et al. · Proceedings of the National Academy of Sciences · 1998 · 326 citations

Life Sciences, Immunology, Oncology +17

Human papillomavirus—the most significant risk determinant of cervical intraepithelial neoplasia

Susanne K. Kjær, Adriaan J. C. van den Brule, Johannes E. Bock et al. · International Journal of Cancer · 1996 · 206 citations · Full text

Medicine, Oncology, Pathology +17

ISCOMs and other saponin based adjuvants

Ian Barr · Advanced Drug Delivery Reviews · 1998 · 185 citations

Life Sciences, Immunology, Immunotherapy +10

A vaccine conjugate of ‘ISCAR’ immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants

Robert W. Tindle, Sarah Croft, Karen Herd et al. · Clinical & Experimental Immunology · 1995 · 64 citations · Full text

Medicine, Immunology, Oncology +17